

Ghana Support for Meningitis A Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Ghana			
2. Grant number: 1619-GHA-28a-X; 16-GHA-08j-Y			
3. Date of Decision Letter: 19 March 2019			
4. Date of the Partnership Framework Agreement: 11 July 2014			
5. Programme title: New Vaccine Support (NVS), Meningitis A Preventive Routine			
6. Vaccine type: Meningitis A			
7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2016 -2019			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2016-2018	2019	Total ²
Programme Budget (US\$)	US\$1,735,548 ³	US\$226,000	US\$1,961,548
10. Vaccine introduction grant (in US\$) US\$ 914,500 disbursed on 3 June 2016			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2016-2018	2019	
Number of Meningitis A vaccines doses		423,000	
Annual Amounts (US\$)	US\$1,735,548 ⁵	US\$226,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1619-GHA-28a-X-C</p> <p>According to the co-financing policy, the Country falls within the group Preparatory transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>							
Type of supplies to be purchased with Country funds in each year	2019						
Number of vaccine doses	180,000						
Number of AD syringes	85,700						
Number of re-constitution syringes	19,800						
Number of safety boxes	1,175						
Value of vaccine doses (US\$)	US\$93,516						
Total co-financing payments (US\$) (including freight)	US\$101,000						
<p>15. Operational support for campaigns: Not applicable</p>							
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. <p>Countries shall report the actual switch date in the first renewal request following the actual implementation.</p> </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td> <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p> </td> <td> <p>To be agreed with Secretariat</p> </td> </tr> </tbody> </table>		Reports and information	Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. <p>Countries shall report the actual switch date in the first renewal request following the actual implementation.</p>	<p>31 March 2019</p> <p>15 May 2019</p>	<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>
Reports and information	Due dates						
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. <p>Countries shall report the actual switch date in the first renewal request following the actual implementation.</p>	<p>31 March 2019</p> <p>15 May 2019</p>						
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>						
<p>17. Financial clarifications: Not applicable</p>							
<p>18. Other conditions: Not applicable</p>							

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 19 March 2019